In HCC cell lines, the SALL4 expression status was associated with histone deacetylase activity, and treatment with a histone deacetylase (HDAC) inhibitor successfully suppressed the proliferation of SALL4-positive HCC cells [34]. Here, HDAC9 is linked to hepatocellular carcinoma.